Enlivex Therapeutics Financials
| ENLV Stock | ILA 545.90 24.30 4.26% |
Enlivex |
Understanding current and past Enlivex Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Enlivex Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Enlivex Therapeutics' assets may result in an increase in income on the income statement.
The data published in Enlivex Therapeutics' official financial statements usually reflect Enlivex Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Enlivex Therapeutics. For example, before you start analyzing numbers published by Enlivex accountants, it's critical to develop an understanding of what Enlivex Therapeutics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Enlivex Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enlivex Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Enlivex Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Enlivex Therapeutics. Please utilize our Beneish M Score to check the likelihood of Enlivex Therapeutics' management manipulating its earnings.
Enlivex Therapeutics Stock Summary
Enlivex Therapeutics competes with Evogene, Kamada, Tower Semiconductor, Elbit Systems, and Nice. Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. ENLIVEX THERAPEUTI operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 50 people.| Foreign Associate | USA |
| Instrument | Israel Stock View All |
| Exchange | Tel Aviv Stock Exchange |
| ISIN | IL0011319527 |
| Business Address | 14 Einstein Street, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | NYSE Composite |
| Website | www.enlivex.com |
| Phone | (972) 2 6208070 |
| Currency | ILA |
You should never invest in Enlivex Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Enlivex Stock, because this is throwing your money away. Analyzing the key information contained in Enlivex Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Enlivex Therapeutics Key Financial Ratios
Generally speaking, Enlivex Therapeutics' financial ratios allow both analysts and investors to convert raw data from Enlivex Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Enlivex Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Enlivex Therapeutics reports annually and quarterly.Enlivex Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Enlivex Therapeutics's current stock value. Our valuation model uses many indicators to compare Enlivex Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Enlivex Therapeutics competition to find correlations between indicators driving Enlivex Therapeutics's intrinsic value. More Info.Enlivex Therapeutics is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Enlivex Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Enlivex Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Enlivex Therapeutics' earnings, one of the primary drivers of an investment's value.Enlivex Therapeutics Systematic Risk
Enlivex Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Enlivex Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Enlivex Therapeutics correlated with the market. If Beta is less than 0 Enlivex Therapeutics generally moves in the opposite direction as compared to the market. If Enlivex Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Enlivex Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Enlivex Therapeutics is generally in the same direction as the market. If Beta > 1 Enlivex Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Enlivex Therapeutics Financials
What exactly are Enlivex Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Enlivex Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Enlivex Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Enlivex Therapeutics investors may use each financial statement separately, they are all related. The changes in Enlivex Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Enlivex Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Enlivex Therapeutics Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Enlivex Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Enlivex has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Enlivex Therapeutics' financials are consistent with your investment objective using the following steps:- Review Enlivex Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Enlivex Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Enlivex Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Enlivex Therapeutics' stock is overvalued or undervalued.
Enlivex Therapeutics April 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Enlivex Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Enlivex Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Enlivex Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Enlivex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Enlivex Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 86.62 | |||
| Value At Risk | (8.93) | |||
| Potential Upside | 13.34 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |